Company news

Evolus, Inc. Common Stock news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

October 28, 2024

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

September 5, 2024

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance

July 30, 2024

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia

July 29, 2024

Evolus Announces Appointment of Albert G. White III to Board of Directors

June 30, 2024

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

June 23, 2024

Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain

June 11, 2024

Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting

May 19, 2024

Evolus Reports First Quarter 2024 Results and Provides Business Update

May 6, 2024

Evolus to Report First Quarter Financial Results on May 7, 2024

April 22, 2024

Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®

April 16, 2024

Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock

March 10, 2024

Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance

March 6, 2024

Evolus Announces Results from European Head-to-Head Filler Trial

February 29, 2024

Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024

February 21, 2024

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance

January 15, 2024

Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications

January 3, 2024

Evolus Enters into Licensing Agreement with Symatese to Exclusively Distribute Next-Generation Dermal Fillers in Europe

December 19, 2023

Evolus Reports Record Third Quarter 2023 Financial Results and Phase II Data for Extra-Strength 40U Formulation of Jeuveau®

November 6, 2023

Evolus to Report Third Quarter 2023 Results

October 24, 2023

Evolus Announces Inducement Grants for New Chief Marketing Officer

August 22, 2023

Evolus Appoints Tomoko Yamagishi-Dressler as Chief Marketing Officer

August 20, 2023

Evolus Unveils New Branding for Flagship Product Jeuveau® to Reflect Growing and Evolving Consumers

August 7, 2023

Evolus Reports Second Quarter 2023 Results and Provides Business Update

August 1, 2023

Evolus Raises Full-Year Revenue Guidance on Record Second Quarter 2023 Revenue

July 26, 2023

Evolus to Report Second Quarter 2023 Results and Provide Business Update

July 18, 2023

Evolus Launches Nuceiva® (botulinum toxin type A) in Italy

June 28, 2023

Evolus Announces Successful Completion of Phase 2 Study Evaluating “Extra-Strength” Dose of Jeuveau ®

June 21, 2023

Evolus Reaches 1 Million Redemptions in its Evolus Rewards™ Patient Loyalty Program

June 7, 2023

Evolus Reports First Quarter 2023 Results and Provides Business Update

May 8, 2023

Evolus Announces Expansion into U.S. Dermal Filler Market with Evolysse™, a First-Generation Cold Technology HA by Symatese

May 8, 2023

Evolus to Report First Quarter 2023 Results and Provide Business Update

May 4, 2023

Evolus Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update

March 7, 2023

Evolus Initiates Nuceiva® Launch in Germany and Austria

February 26, 2023

Evolus to Report Fourth Quarter and Year End 2022 Results and Provide Business Update

February 21, 2023

Evolus Receives Regulatory Approval for Nuceiva® in Australia

January 22, 2023

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Net Revenue, Projects Profitability by Year-End 2023, and Sets $500 Million 2028 Jeuveau®/Nuceiva® Revenue Aspiration

January 17, 2023

Evolus Extends Term of Credit Facility with Pharmakon Advisors

December 7, 2022

Evolus Reports Third Quarter 2022 Results and Provides Business Update

November 7, 2022

Evolus to Report Third Quarter 2022 Results and Provide Business Update

October 24, 2022

Evolus Broadens Its International Presence with Nuceiva® Launch in Great Britain

October 3, 2022

Evolus Concludes Certain Royalty Payments; Financial Profile Improves Significantly Starting in the Fourth Quarter of 2022

September 20, 2022

Evolus Announces Inducement Grants for New Chief Financial Officer

September 5, 2022

Evolus Appoints Sandra Beaver as Chief Financial Officer

August 29, 2022

Evolus Reports Second Quarter 2022 Results and Provides Business Update

August 1, 2022

Evolus to Report Second Quarter 2022 Results and Provide Business Update

July 18, 2022

Evolus Launches New Campaign Inspiring Consumers to “Switch Your Tox and Love Evolus Forever”

July 18, 2022

Evolus Successfully Completes Patient Enrollment in Phase II Clinical Study Evaluating “Extra-Strength” Dose of Jeuveau®

July 11, 2022

Evolus Celebrates Third Anniversary of the Launch of Jeuveau® in the United States

May 17, 2022

Evolus Reports First Quarter 2022 Results and Provides Business Update

May 9, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 16 decks. Every deck is listed under its year.